Table 1 Peripheral blood myeloid... | American Society of Hematology

Table 1

Peripheral blood myeloid progenitor cell–mobilizing effects of 300 mg intravenous natalizumab in 4 MS patients

	BFU-E colonies, no.					CFU-G/-M/-GM colonies, no.
	Before infusion	1 h after infusion	24 h after infusion	48 h after infusion	72 h after infusion	Before infusion	1 h after infusion	24 h after infusion	48 h after infusion	72 h after infusion
Patient 1	1	10	88	100*	100*	0	5	22	43	39
Patient 2	4	34	100*	100*	100*	1	10	38	34	40
Patient 3	10	100*	100*	100*	67	5	21	27	10	11
Patient 4	50	100*	100*	100*	100*	1	44	25	18	20
Median	7	67	100	100	100	1	15.5	26	26	29.5
P†	—	.08	.004	.005	.009	—	.12	.005	.06	.05

	BFU-E colonies, no.					CFU-G/-M/-GM colonies, no.
	Before infusion	1 h after infusion	24 h after infusion	48 h after infusion	72 h after infusion	Before infusion	1 h after infusion	24 h after infusion	48 h after infusion	72 h after infusion
Patient 1	1	10	88	100*	100*	0	5	22	43	39
Patient 2	4	34	100*	100*	100*	1	10	38	34	40
Patient 3	10	100*	100*	100*	67	5	21	27	10	11
Patient 4	50	100*	100*	100*	100*	1	44	25	18	20
Median	7	67	100	100	100	1	15.5	26	26	29.5
P†	—	.08	.004	.005	.009	—	.12	.005	.06	.05

Colony-forming activity was determined after plating 4×10⁵ MNCs in 24-well plates before and 1, 24, 48, and 72 hours following the initial infusion of natalizumab.

— indicates not applicable.

In these particular culture plates, at least 100 single BFU-Es were discernible. In fact, the plating efficacy was unexpectedly higher, so that some of the BFU-E growth was not clearly attributable to individual colonies.

†

Statistical significance expressed as P value compared with baseline (time = before) using the 2-sided paired t test.

View Large

This Feature Is Available To Subscribers Only